title: Antiemetic prophylaxis of cancer chemotherapy-induced nausea and vomiting with cinnarizine and lorazepam.
abstract: An oral combination of cinnarizine and lorazepam was studied for the prophylaxis of nausea and vomiting induced by strongly emetogenic cancer chemotherapy. 56% of 59 chemotherapy courses in 29 patients were completed without emesis. Of the 42 cisplatin-containing regimens, 52% were without vomiting and 62% free of nausea. A further 11 patients (17 courses) received non-cisplatin emetogenic chemotherapy. In this group full emetic control was achieved in 65% of the courses. Diarrhea in 4% of the courses was the only side effect of this new oral combination.
authors.affiliation: Department of Medicine, Kantonsspital, St. Gallen, Switzerland.
authors.forename: C H
authors.initials: CH
authors.lastname: Wilder-Smith
authors.forename: H J
authors.initials: HJ
authors.lastname: Senn
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000932:Antiemetics; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002936:Cinnarizine / Q000008:administration & dosage / Q000627:therapeutic use*; D002945:Cisplatin / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008140:Lorazepam / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D010865:Pilot Projects; D011446:Prospective Studies; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D002936:Cinnarizine; D008140:Lorazepam; D002945:Cisplatin